TTF1 and adenocarcinoma: Its membranous expression demonstrates high specificity (97.4%–100%) for distinguishing SCC from adenocarcinoma (Gómez-Morales et al., 2013; Galindo et al., 2020), thereby serving as a reliable adjunct to established markers such as TTF-1 (positive in adenocarcinoma) and p63 (positive in SCC) (Sharma et al., 2022).